Walsh & Associates’s Concentrix CNXC Stock Holding History

Walsh & Associates’s Portfolio CNXC Stock Details CNXC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8	Closed	-$219	–	254
2026 Q1	$219	Buy	+8	New	+$284	﹤0.01%	267

Other funds holding CNXC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Pzena Investment Management New York $34.1B AUM 23.81% 1-Year Est. Return

KGI

Kopernik Global Investors Tampa, Florida $1.63B AUM 27.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

GBL

Groupe Bruxelles Lambert Brussels, Belgium $62.2M AUM 57.6% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Walsh & Associates's CNXC Position: Q2 2026 in Review

Walsh & Associates sold out of Concentrix (CNXC) in Q2 2026, closing a stake of 8 shares — an estimated $219 sold.

Walsh & Associates first reported a position in CNXC in Q1 2026 and held it in 1 quarter. The position peaked at $219 in Q1 2026. 269 funds tracked by Wall St. Rank hold CNXC as of Q2 2026.

Walsh & Associates reported no remaining Concentrix position as of Q2 2026 after selling out during the quarter.
Walsh & Associates sold 8 Concentrix shares in Q2 2026, an estimated $219.
Walsh & Associates first reported a position in Concentrix in Q1 2026 and held it in 1 quarter.
Walsh & Associates's Concentrix position peaked at $219 in Q1 2026.
269 funds tracked by Wall St. Rank held Concentrix as of Q2 2026.

Based on Walsh & Associates's 13F filing for Q2 2026, filed 21 Jul 2026.